Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe diseaseYildirim Dogan, Niek P. van Til, Axel Schambach et al.|Molecular Therapy — Methods & Clinical Development|2022Cited by 16
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestationsJohn K. Yoon, Niek P. van Til, Jeffrey W. Schindler et al.|Molecular Therapy|2024Cited by 5
Screening of Chimeric GAA Variants in a Preclinical Study of Pompe Disease Results in Candidate Vector for Hematopoietic Stem Cell Gene TherapyYildirim Dogan, Niek P. van Til, Cecilia Barese et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 2
Flow Cytometry Assay to Monitor Effectiveness of Gene Therapy Correction in Peripheral Blood Mononuclear Cells of Gaucher Disease Type I PatientsCecilia Barese, Chris Mason, Michael T. Waring et al.|Blood|2018Cited by 1
Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestationsJohn K. Yoon, Niek P. van Til, Jeffrey W. Schindler et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0